Tandem Therapeutics wins CHF 150,000 to fight fibrotic cancer

Please login or
register
24.02.2023

The biotech startup Tandem Therapeutics was awarded CHF 150,000 by the Venture Kick jury to develop its novel solution for the treatment of fibrotic cancers and fibrosis. The ETH spin-off is focusing on a technology that precision targets the extracellular matrix, the meshwork of proteins surrounding the cells.

Most drug development is focused on targeting cells, overlooking the extracellular matrix that surrounds the cells which, if present in excess, is linked to therapeutic resistance, limited access, and poor patient outcomes in fibrotic cancers and organ fibrosis.

Tandem Therapeutics is developing first-in-class peptide therapeutics that target and treat the extracellular matrix barrier. The startup’s primary focus is fibrotic tumors with high matrix burden and a high-unmet medical need. The startup’s innovative approach offers a highly selective, safe, and promising new way to treat these complex and intractable diseases.

Even with phenomenal advances in cancer treatments, many fibrotic tumors show no response to existing therapies, leaving millions of patients with no solutions. Tandem Therapeutics’ technology has the potential to play a major role in the market of targeted oncology therapy, which is expected to grow by over USD 130 billion per year by 2030.

Tandem Therapeutics was co-founded by Mamta Chabria (CEO), a senior scientist at the Laboratory of Applied Mechanobiology at ETH and former scientific fellow at F. Hoffmann-La Roche; Viola Vogel, who heads the Laboratory of Applied Mechanobiology; and Martin Behe, group leader at the Paul Scherrer Institute’s Center for Radiopharmaceutical Sciences. The startup will invest the CHF 150,000 awarded by Venture Kick in expanding its team and accelerating its business development activities.

“Venture kick helped propel us into a sense of urgency that startups need early on,” said Chabria. “The program is like a ‘Swiss knife’ for our entrepreneurial needs, challenging our assumptions and providing actionable insights. The access to experts with both founder and investor experiences has been invaluable in refining our plan.”

(Press release)

0Comments

More news about

Tandem Therapeutics AG

Company profiles on startup.ch

Tandem Therapeutics AG

rss